High dose cyclosporin with etoposide - Toxicity and pharmacokinetic interaction in children with solid tumours

British Journal of Cancer

Volumn 77, Issue 12, 1998, Pages 2304-2309

  Bisogno, G ^a   Cowie, F ^a   Boddy, A ^b   Thomas, H D ^b   Dick, G ^a   Pinkerton, C R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cyclosporin; Drug resistance; Etoposide; Paediatric; Solid tumour

Indexed keywords

ANTINEOPLASTIC ALKALOID; BILIRUBIN; CREATININE; CYCLOSPORIN; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; UREA;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER DYSFUNCTION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOLID TUMOR;

EID: 0031748757     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.383     Document Type: Article

References (34)

1. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J and Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835-842
2. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH and Bleehen NM (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610-618
3. Bourhis J, Benard J, Hartmann O, Boccon Gibod L, Lemerle J and Riou G (1989) Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 81: 1401-1405
4. Bourhis J, Hartmann O, DeVathaire F, Terrier Lacombe MJ, Boccon Gibod L, Lemerle J, Riou G and Benard J (1991) Expression of MDR1 and GST pi genes in 35 advanced neuroblastomas. Prog Clin Biol Res 336: 127-134
5. Brophy NA, Marie JP, Rojas RA, McFall PJ, Smith SD and Sikic BI (1994) Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: A critical evaluation by four techniques. Leukemia 8: 327-335
6. Cairo MS, Siegel S, Anas N and Sender L (1989) Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 49: 1063-1066
7. Chan HS, Thorner PS, Haddad and Ling V (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689-704.
8. Chan H, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H and Ling V (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608-1614
9. Chan HS, DeBoer G, Thorner PS, Haddad G, Gallie BL and Ling V (1994a) Multidrug resistance. Clinical opportunities in diagnosis and circumvention. Hematol Oncol Clin N Am 8: 383-410.
10. Chan HSL, DeBoer G and Kingston JE (1994b) Cyclosporin-modulated chemotherapy with focal cryo/laser therapy: a new approach to retinoblastoma. Anti-Cancer Drugs 5: 57
11. Corrias MV, Cornaglia Ferraris P, Di Martino D, Stenger AM, Lanino E, Bomi L and Tonini GP (1990) Expression of multiple drug resistance gene, MDR1, and N-myc oncogene in an Italian population of human neuroblastoma patients. Anticancer Res 10: 897-902
12. Cowie F and Pinkerton CR (1994) Enhanced toxicity of dactinomycin and vincristine by cyclosporin given to reverse multidrug resistance. J Clin Oncol 12: 1998-1999
13. Cowie FJ, Pinkerton CR, Phillips M, Dick G, Judson I, McCarthy PT and Flanagan RJ (1995) Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer 71: 877-881
14. Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C and Bunting P (1993) Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53: 4837-4842
15. Fridborg H, Jonsson B, Nygren P, Csoka K, Nilsson K, Oberg G, Kristensen J, Bergh J, Tholander B and Olsen L (1994) Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours. Br J Cancer 70: 11-17
16. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J and Harding MW (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anti-Cancer Drugs 8: 125-140
17. Gibaldi M and Perrier D (1982) Pharmacokinetics. Drugs and Pharmaceutical Sciences. Marcel Dekker: New York
18. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C and Guerci O (1995) Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 85: 2147-2153
19. Helson C, Zahn Z and Helson L (1994) Reversion of P-glycoprotein mediated multidrug resistance to vincristine and adriamycin by PSC-833, a cyclosporine derivative in human neuroblastoma cell lines. Int J Oncol 5: 1037-1042
20. Kuttesch JFJ, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT and Houghton PJ (1996) P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhahdomyosarcoma. J Clin Oncol 14: 886-900
21. Leyland-Jones B, Dalton W, Fisher GA and Sikic BI (1993) Reversal of multidrug resistance to cancer chemotherapy. J Clin Oncol 72: 3484-3488
22. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M and Dalton W (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11(9): 1652-1660
23. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP and Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cxclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635-1642
24. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J and Sikic BI (1993) Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. J Clin Oncol 72: 3502-3514
25. McLeod HL (1994) Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction? Eur J Cancer 30: 2039-2041
26. Merlin J, Guerci A, Marchal S, Missoum N, Ramacci C, Humhert JC, Tsuruo T and Guerci O (1994) Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 84: 262-269
27. Millward MJ, Newell DR, Yuen K, Matthews JP, Balmanno K, Charlton CJ, Gumbrell L, Lind MJ, Chapman F and Proctor M (1995) Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. Cancer Chemother Pharmacol 37: 161-167
28. Pinkerton CR (1996) Multidrug resistance reversal in childhood malignancies - potential for a real step forward? Eur J Cancer 32: 641-644
29. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS and Tewksbury DA (1994) The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. J Clin Oncol 74: 834-841
30. Serra M, Scotlandi K, Manara MC, Maurici D, Benini S, Sarti M, Campanacci M and Baldini N (1995) Analysis of P-glycoprotein expression in osteosarcoma. Eur J Cancer 31: 1998-2002
31. Stein U, Shoemaker RH and Schlag PM (1996) MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Eur J Cancer 32: 86-92
32. Theis JG, Liau Chu M, Chan HS, Doyle J, Greenberg ML and Koren G (1995) Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol 13: 2508-2516
33. Vergier B, Cany L, Bonnet F, Robert J, deMascarel A and Coindre JM (1993) Expression of MDR1/P glycoprotein in human sarcomas. Br J Cancer 68: 1221-1226
34. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL and Sikic BI (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10: 1624-1634